Invader UGT1A1 Molecular Assay Wins U.S. FDA Approval
Filed in archive Genomics, Proteomics and Bioinformatics by ruth on August 26, 2005
cancer drug Camptosar (made by Pfizer, Inc., Generic name: Irinotecan).
"For a patient with a particular UGT1A1 gene variation, a dose of irinotecan that is safe for another person might be too high for this patient, raising the risk of certain side effects. There is, we think, a lot of potential for this to be applied to other drugs," FDA officials said.
Another step into personalised medical treatment.
Read Reuters report here.
Permalink: Invader UGT1A1 Molecular Assay Wins U.S. FDA Approval
Tags:
colon cancer biotech ugt1a1 molecular molecular+assay ugt1a1+molecular invader+ugt1a1
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/8724







